The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival.
about
Fluorodeoxyglucose positron emission tomography and tumor marker expression in non-small cell lung cancer.Evaluation of elastix-based propagated align algorithm for VOI- and voxel-based analysis of longitudinal (18)F-FDG PET/CT data from patients with non-small cell lung cancer (NSCLC)Positron emission tomography/computerized tomography in lung cancer.Prognostic Value of Primary Tumor Uptake on F-18 FDG PET/CT in Patients with Invasive Ductal Breast CancerCorrelation between (18)f-fluorodeoxyglucose uptake and epidermal growth factor receptor mutations in advanced lung cancerFDG-PET SUVmax combined with IASLC/ATS/ERS histologic classification improves the prognostic stratification of patients with stage I lung adenocarcinoma.Revisiting the prognostic value of preoperative (18)F-fluoro-2-deoxyglucose ( (18)F-FDG) positron emission tomography (PET) in early-stage (I & II) non-small cell lung cancers (NSCLC).Frequency of lymph node metastasis according to the size of tumors in resected pulmonary adenocarcinoma with a size of 30 mm or smaller[18F]-fluorodeoxyglucose positron emission tomography can contribute to discriminate patients with poor prognosis in hormone receptor-positive breast cancerThe role of (18)F-FDG PET in the differentiation between lung metastases and synchronous second primary lung tumours.Maximum standardized uptake value on 18F-fluoro-2-deoxy-glucose positron emission tomography/computed tomography and glucose transporter-1 expression correlates with survival in invasive ductal carcinoma of the pancreas.Difference in prognostic values of maximal standardized uptake value on fluorodeoxyglucose-positron emission tomography and cyclooxygenase-2 expression between lung adenocarcinoma and squamous cell carcinomaStandardized uptake value of ¹⁸F-fluorodeoxyglucose positron emission tomography for prediction of tumor recurrence in breast cancer beyond tumor burden.Implications of false negative and false positive diagnosis in lymph node staging of NSCLC by means of ¹⁸F-FDG PET/CT.Predictive significance of standardized uptake value parameters of FDG-PET in patients with non-small cell lung carcinoma.Metabolic Characteristics of Advanced Biliary Tract Cancer Using 18F-Fluorodeoxyglucose Positron Emission Tomography and Their Clinical ImplicationsImpact of point spread function modelling and time of flight on FDG uptake measurements in lung lesions using alternative filtering strategiesMediastinal staging of NSCLC with endoscopic and endobronchial ultrasound.Predictive value of 18F-FDG PET and CT morphologic features for recurrence in pathological stage IA non-small cell lung cancer.Clinical Correlation Between Tumor Maximal Standardized Uptake Value in Metabolic Imaging and Metastatic Tumor Characteristics in Advanced Non-small Cell Lung Cancer.Integrated FDG-PET/CT does not make invasive staging of the intrathoracic lymph nodes in non-small cell lung cancer redundant: a prospective study.Clinical significance of dual-time-point 18F-FDG PET imaging in resectable non-small cell lung cancer.Positron emission tomography with [(18)F]-3'-deoxy-3'fluorothymidine (FLT) as a predictor of outcome in patients with locally advanced resectable rectal cancer: a pilot studyPET/CT in oncology: for which tumours is it the reference standard?Identification of false-negative and false-positive diagnoses of lymph node metastases in non-small cell lung cancer patients staged by integrated (18F-)fluorodeoxyglucose-positron emission tomography/computed tomography: A retrospective cohort studFDG PET/CT and mediastinal nodal metastasis detection in stage T1 non-small cell lung cancer: prognostic implications.Predictive and prognostic value of FDG-PET.The maximum standardized FDG uptake on PET-CT in patients with non-small cell lung cancerPET/CT for staging and monitoring non small cell lung cancerPositron Emission Tomography (PET) radiotracers in oncology--utility of 18F-Fluoro-deoxy-glucose (FDG)-PET in the management of patients with non-small-cell lung cancer (NSCLC).Integrated FDG-PET/CT imaging is useful in the approach to carcinoid tumors of the lung.Risk factors of postoperative recurrences in patients with clinical stage I NSCLC.Maximum standardized uptake value in (18)F-fluoro-2-deoxyglucose positron emission tomography is associated with advanced tumor factors in esophageal cancer.Correlation of [18F]-2-fluoro-deoxy-D-glucose positron emission tomography standard uptake values with the cellular composition of stage I nonsmall cell lung cancer.PET/CT assessment of neuroendocrine tumors of the lung with special emphasis on bronchial carcinoids.The role of PET/CT as a prognosticator and outcome predictor in lung cancer.MHC class I chain-related molecule A and B expression is upregulated by cisplatin and associated with good prognosis in patients with non-small cell lung cancer.Prognostic value of the standardized uptake value maximum change calculated by dual-time-point (18)F-fluorodeoxyglucose positron emission tomography imaging in patients with advanced non-small-cell lung cancer.Radiomic Analysis using Density Threshold for FDG-PET/CT-Based N-Staging in Lung Cancer Patients.Preoperative predictors of distant recurrence in patients with clinical stage IA lung adenocarcinoma undergoing complete resection.
P2860
Q30419853-0D895E68-9E0A-4380-B59B-90CEE8265179Q30926992-5B72A3BF-003E-4511-A162-874869488ECFQ33657999-76B9DCF3-0A3B-4DDD-AFD3-78C9E89DAFE8Q33704435-526CE68E-7397-45C1-BD48-8166C6F46ECFQ33704537-2DF0781F-D5E7-45E2-9D13-39D0F3682F55Q33724626-BBD5BECC-2113-4E09-882A-81DDDD1A7CD6Q33751205-923FAE4A-5116-40C3-8C10-F85F0280F6D4Q34041741-C2734F0F-8E79-43B6-9BA1-A9E5A8A98A80Q34105060-12E06B5B-BBE2-4508-88DF-DF634B2FD110Q34166842-7A3B8EDD-8C01-47C6-91F0-3FB7A4AEB388Q34243313-03A1F705-4174-439D-96F6-1195C51A82B8Q34623382-4CA47D89-13E7-4433-BD60-38101D7C0E58Q35021092-DAD5A233-DC82-48DA-9C45-364F7D8D2EE5Q35036508-FCEAE69E-105A-4D30-948C-79278780C13BQ35240586-511EED6B-34CE-4262-B0ED-8779E1EF5668Q35915703-E2FD16F6-33A9-49DB-B093-7828A0522FB0Q35983497-9A12E0E2-6B6B-47BE-945B-35660B928AFDQ36107597-699E5AA6-00CF-4920-A1D9-9DD64CA3B52CQ36151953-9A389089-A9BD-4487-ACCB-1C3F331168BEQ36195043-08BF22E7-B517-458B-BF64-28BBEAF4B25AQ36225895-2BAE6844-F3A1-4389-88D4-4A4AEEE6D652Q36337401-D5CFEF28-C67D-4A16-8B35-705CA470133BQ36861827-B3DDCDC1-A9EF-4294-BC2D-ADC41C6F2D0AQ36963748-36F55543-1AC9-444A-B70D-7A931FFDC400Q37060407-794FA11A-00BE-424D-B968-13391A8D848EQ37063199-30247AC0-21EB-4445-8BF6-F14EE4F65113Q37129057-CE792971-06A7-4953-8C70-2C8E209167BEQ37275716-DD5C6604-C2A5-45C3-B9CD-318907E758EFQ37292826-8E5AFB82-86EA-4C9E-B796-AC0A136C13D0Q37301288-7C97D1BD-AD0C-45CC-BA5D-2DB6ED2F6BB3Q37427631-0DA95B91-8C8F-4C24-846E-A85A8320B39AQ37493587-CBEFB181-AFF7-45AA-B9CB-94C97384030AQ37567827-D8C6BD55-4611-4C97-8621-488B7C78F156Q37763664-52B79E75-435C-49EB-A620-88D4105066E0Q38213643-CB925819-B6ED-400A-8481-4D055426CA1AQ38715401-2FB59AFB-F937-4097-A7C9-26BB3F3DD946Q38789090-D2785AD6-779C-494F-80FA-B56AAD2311E0Q38860955-8F1261E7-D367-4E6C-B522-306EF3AF9D36Q38931317-859566E3-ADFD-4856-AE60-1442BE346F0AQ38973825-2C6398FD-EC3A-4991-866E-8FEF9822D1B5
P2860
The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
The maximum standardized uptak ...... age, recurrence, and survival.
@ast
The maximum standardized uptak ...... age, recurrence, and survival.
@en
type
label
The maximum standardized uptak ...... age, recurrence, and survival.
@ast
The maximum standardized uptak ...... age, recurrence, and survival.
@en
prefLabel
The maximum standardized uptak ...... age, recurrence, and survival.
@ast
The maximum standardized uptak ...... age, recurrence, and survival.
@en
P1476
The maximum standardized uptak ...... tage, recurrence, and survival
@en
P2093
Alfred A Bartolucci
Buddhiwardhan Ohja
P304
P356
10.1016/J.JTCVS.2004.11.007
P407
P577
2005-07-01T00:00:00Z